Halozyme Therapeutics, Inc. (HALO)
108.64
+0.47
(+0.43%)
USD |
NASDAQ |
Aug 24, 16:00
108.64
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Net Income (Quarterly) : 229.91M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 229.91M |
| March 31, 2026 | 150.05M |
| December 31, 2025 | -141.59M |
| September 30, 2025 | 175.22M |
| June 30, 2025 | 165.16M |
| March 31, 2025 | 118.10M |
| December 31, 2024 | 137.01M |
| September 30, 2024 | 137.01M |
| June 30, 2024 | 93.24M |
| March 31, 2024 | 76.82M |
| December 31, 2023 | 85.39M |
| September 30, 2023 | 81.84M |
| June 30, 2023 | 74.75M |
| March 31, 2023 | 39.62M |
| December 31, 2022 | 57.70M |
| September 30, 2022 | 61.63M |
| June 30, 2022 | 22.68M |
| March 31, 2022 | 60.11M |
| December 31, 2021 | 66.77M |
| September 30, 2021 | 216.59M |
| June 30, 2021 | 91.46M |
| March 31, 2021 | 27.90M |
| December 31, 2020 | 73.16M |
| September 30, 2020 | 36.21M |
| June 30, 2020 | 25.82M |
| Date | Value |
|---|---|
| March 31, 2020 | -6.103M |
| December 31, 2019 | -34.40M |
| September 30, 2019 | -25.02M |
| June 30, 2019 | -14.62M |
| March 31, 2019 | 1.796M |
| December 31, 2018 | -2.126M |
| September 30, 2018 | -27.85M |
| June 30, 2018 | -22.89M |
| March 31, 2018 | -27.46M |
| December 31, 2017 | 123.88M |
| September 30, 2017 | 2.749M |
| June 30, 2017 | -30.76M |
| March 31, 2017 | -32.90M |
| December 31, 2016 | -27.39M |
| September 30, 2016 | -28.95M |
| June 30, 2016 | -26.88M |
| March 31, 2016 | -19.82M |
| December 31, 2015 | 4.318M |
| September 30, 2015 | -24.46M |
| June 30, 2015 | 3.019M |
| March 31, 2015 | -15.11M |
| December 31, 2014 | -5.274M |
| September 30, 2014 | -20.28M |
| June 30, 2014 | -16.27M |
| March 31, 2014 | -26.55M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Incyte Corp. | 585.60M |
| Neurocrine Biosciences, Inc. | 144.40M |
| AVITA Medical, Inc. | -7.663M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 481.00M |
| Total Expenses (Quarterly) | 251.09M |
| EPS Diluted (Quarterly) | 1.897 |
| Enterprise Value | 14.25B |
| Gross Profit Margin (Quarterly) | 77.40% |
| Profit Margin (Quarterly) | 47.80% |
| Earnings Yield | 3.08% |
| Operating Earnings Yield | 7.18% |
| Normalized Earnings Yield | 5.012 |